14.92 USD
-0.36 (-2.36%)
At close: Jan 30, 2026
15.21 USD
+0.29 (+1.94%)
After Hours: 1/30/2026, 8:03:45 PM
Taking everything into account, MCRB scores 2 out of 10 in our fundamental rating. MCRB was compared to 525 industry peers in the Biotechnology industry. While MCRB seems to be doing ok healthwise, there are quite some concerns on its profitability. MCRB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- MCRB had negative earnings in the past year.
- MCRB had a negative operating cash flow in the past year.
- In the past 5 years MCRB reported 4 times negative net income.
- MCRB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- MCRB has a Return On Assets of 3.76%. This is amongst the best in the industry. MCRB outperforms 90.48% of its industry peers.
- MCRB has a Return On Equity of 12.34%. This is amongst the best in the industry. MCRB outperforms 93.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 12.34% | ||
| ROIC | N/A |
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MCRB has a Profit Margin of 1536.75%. This is amongst the best in the industry. MCRB outperforms 99.43% of its industry peers.
- The Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 1536.75% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MCRB has more shares outstanding than it did 1 year ago.
- MCRB has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -10.66, we must say that MCRB is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of MCRB (-10.66) is worse than 72.76% of its industry peers.
- MCRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.66 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 2.30 indicates that MCRB has no problem at all paying its short term obligations.
- MCRB's Current ratio of 2.30 is on the low side compared to the rest of the industry. MCRB is outperformed by 72.76% of its industry peers.
- A Quick Ratio of 2.30 indicates that MCRB has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.30, MCRB is doing worse than 70.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.3 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 73.57% over the past year.
EPS 1Y (TTM)73.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 21.59% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y103.73%
EPS Next 2Y24.24%
EPS Next 3Y12.91%
EPS Next 5Y21.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MCRB. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MCRB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MCRB's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.24%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
- No dividends for MCRB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SERES THERAPEUTICS INC / MCRB FAQ
What is the ChartMill fundamental rating of SERES THERAPEUTICS INC (MCRB) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MCRB.
What is the valuation status for MCRB stock?
ChartMill assigns a valuation rating of 0 / 10 to SERES THERAPEUTICS INC (MCRB). This can be considered as Overvalued.
What is the profitability of MCRB stock?
SERES THERAPEUTICS INC (MCRB) has a profitability rating of 2 / 10.
What is the financial health of SERES THERAPEUTICS INC (MCRB) stock?
The financial health rating of SERES THERAPEUTICS INC (MCRB) is 5 / 10.